Astal Laboratories Ltd — Important, 15-05-2026: Company Update

Astal Laboratories has submitted a Monitoring Agency Report confirming no deviation from the objectives of its preferential issue. The issue, initially for 3,04,58,187 equity shares, was revised to 3,04,25,632 equity shares at INR 91.00 each, totaling INR 276.87 Cr. The change involved settling 32,555 shares in cash due to a shareholder's disqualification. The funds were utilized to acquire Sriven Pharmachem India Private Limited, aiming to expand the company's product portfolio and become a fully integrated pharmaceutical manufacturer.